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Abstract: A series of 2-phenyloxazole-4-carboxamides (4a-o) 
behaving as competitive inhibitors of human monoamine oxidases 
(MAOs) with good selectivity toward the MAO-B isoform is described. 
Some derivatives were also able to inhibit MAO activity in NGF–
differentiated PC12 cells, taken as a cellular model. In particular, 
derivative 4a exerts the highest inhibitory effect without compromising 
cell viability. Molecular docking analysis allowed rationalizing the 
experimentally observed binding affinity and selectivity. 
Introduction 
Monoamine oxidases (MAOs, EC 1.4.3.4) are flavin adenine 
dinucleotide (FAD)-containing enzymes, which catalyze the 
oxidative deamination of neurotransmitter amines and a wide 
variety of amine xenobiotics, including therapeutic drugs. The two 
MAO-A and MAO-B isoforms (70% of sequence identity), are 
bound to the outer mitochondrial membrane and expressed in 
different proportion in the majority of mammalian tissues, e.g., 
intestine, liver, placenta and brain. In human brain, MAO-A seems 
mainly localized at the catecholaminergic neurons while MAO-B 
at serotoninergic neurons and astrocytes.[1,2] MAO-A preferentially 
metabolizes serotonin, adrenaline and noradrenaline, whereas 
MAO-B preferentially metabolizes phenylethylamine and 
benzylamine, with an overlapping metabolizing activity of both 
enzymes on adrenalin and dopamine.[2,3] 
Being involved in the catabolism of neurotransmitters, MAOs are 
established pharmacological targets in various neurological, 
psychiatric and neurodegenerative diseases.[4-6] Indeed, MAO 
inhibitors lower the catabolism of neurotransmitters, with a 
concomitant decrease also in the generation of corresponding 
aldehydes, ammonia and hydrogen peroxide (reaction products) 
that, at high concentration, may be toxic and linked to a condition 
of oxidative stress, which is at the basis of various pathologies. 
MAO-A inhibitors have therapeutic utility mainly as anxiolytic and 
antidepressant (moclobemide and befloxatone), whereas MAO-B 
inhibitors are typically used for the treatment of Parkinson’s 
disease, e.g. deprenyl as irreversible and safinamide as 
reversible inhibitors,[4] as well as potential drugs in the therapy of 
Alzheimer’s disease.[7] 
Various generations of MAO inhibitors have been developed so 
far[8,9] with the aim of reducing their adverse side-effects such as 
hypertensive crisis, liver toxicity or sleep disturbance and 
headache, observed with some MAO-A inhibitors. Starting more 
than fifty years ago with hydrazine derivatives (such as 
iproniazide) and then propargylamine derivatives (clorgyline, 
deprenyl, rasagiline), the last generation of MAO inhibitors 
includes a wide variety of chemotypes obtained from synthetic 
compounds or natural products, such as chalcones,[10,11] 
pyrazoles,[12,13] chromones,[14,15] coumarins,[16,17] isatin 
derivatives,[18] thiazolidindiones[8,9,19] and polyamine 
analogues.[20] In particular, most recent efforts pointed to the 
development of reversible and MAO-B selective compound, such 
as safinamide (Ki of about 500nM)[21] or chlorophenyl-1-(2-
hydroxy-4-methoxyphenyl)penta-2,4-dien-1-one, the latter 
showing an IC50 of 4.51nM.[22] 
 Additionally, the development of dual target agents able to act 
both on MAO-B and other targets involved in the same pathology 
(such as acetylcholinesterase or butyryl-cholinesterase for 
Alzheimer’s disease) appears very promising and, consequently, 
novel scaffolds endowed with two moieties for the two targets 
have been designed.[23-25] 
A key role in the development of selective compounds was played 
by the resolution of the human MAO-A[26] and MAO-B crystal 
structures,[27] which may be considered a milestone in the 
investigation of the structural bases of substrate and inhibitor 
selectivity between the two isoforms. Indeed, the active site of the 
two isoforms consists of a hydrophobic cavity that differs in few 
structural details. In MAO-B, the presence of different “gating 
residues” conformation results in an important cavity plasticity, 
which may switch from a single binding pocket, when large 
inhibitors are bound, to a dipartite cavity when smaller ligands 
occupy the catalytic site in front of the FAD cofactor.[28] This 
structural behaviour has important pharmacological 
consequences, because large inhibitors are generally highly 
selective towards MAO-B. Recently, large polyamine analogues 
that can act as substrate or inhibitors with MAO-B selectivity were 
described.[20] Nevertheless, as the ideal drug candidate has not 
been achieved so far, researchers continued to explore this field. 
In the frame of a screening campaign of a huge library of natural 
and synthetic compounds, 2-phenyloxazole (Figure 1) was found 
to be a promising scaffold. The structural relationships of this 
scaffold with the non-selective, irreversible MAOs inhibitor 
isocarboxazid moved us to prepare a focused library of 
derivatives differently substituted at the phenyl ring and bearing 
an amide group at position 4, to be evaluated as potential novel 
inhibitors on both hrMAO-A and hrMAO-B allowing the attainment 
of the kinetic parameters and the selectivity index. 
 
 
 
Figure 1. Structural relationships between isocarboxazid and the reported 2-
phenyloxazoles-4-carboxamide. 
 
Considering the involvement of MAOs in neurons, we tested these 
potential MAO inhibitors taking advantage of nerve growth factor 
(NGF) differentiated PC12 cells, an useful cellular model system 
that recapitulates neuronal characteristics[29] and that has been 
extensively used for investigating MAO inhibitors.[30] Finally, 
docking calculations were performed to discuss structure–activity 
relationships (SAR) and rationalize the observed isoform 
selectivity of the reported MAO-B inhibitors. 
Results and Discussion 
Chemistry 
 
The synthesis of the oxazole core structure of the target 
compound library is based on a one-pot procedure presented in 
the literature.[31,32] Commercially available aldehydes 1a-c were 
condensed with L-serine methyl ester hydrochloride and then 
oxidized in situ in the presence of BrCCl3/1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) to afford the 
corresponding 2,4-oxazole derivatives 2. The latter ones were 
then cleaved in the presence of lithium hydroxide to form the 
corresponding acids 3, which subsequently were coupled to the 
appropriate amines in the presence of 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate (HATU) to provide the 
desired compounds 4a-i (Scheme 1). In the case of the 
synthesized aldehyde 1d,[33] this straightforward synthesis didn’t 
furnish the desired compounds 4m-o. For this reason, aldehyde 
1d was first protected (1e) and afterwards condensed with L-
serine methyl ester hydrochloride and oxidized to provide the 
corresponding acid 3e. Coupling of acid 3e with the appropriate 
amines provided the intermediate compounds 4j-l, which were 
subsequently deprotected in the presence of BBr3 to afford the 
final compounds 4m-o (Scheme 1). 
 
Scheme 1. Reagents and Conditions: a) i) L-serine methyl ester hydrochloride, 
MgSO4, Et3N, THF, r.t. overnight, ii) BrCCl3, DBU, dichloromethane (DCM), 0 °C 
for 2 h then overnight at r.t. (15–32%); b) BnBr, K2CO3, acetone reflux, 4 h; c) 
LiOH·H2O, THF, H2O, 80 °C, 3 h (91–94%); d) various amines, HATU, N,N-
diisopropylethylamine (DIPEA), DCM, reflux, 4 h (50–85%); e) BBr3, DCM, -
78 °C for 1 h then overnight at r.t. (80–85%). 
Inhibitory effect on hrMAO-A and hrMAO-B 
 
To evaluate the ability of 4a-o (Table 1) to interact with MAOs, 
these compounds were tested in vitro versus both hrMAO-A and 
hrMAO-B. After having verified that the new 2-phenyloxazole-4-
carboxamides did not behave as substrates, they were assayed 
as potential MAO inhibitors. 
All the compounds were found to act as competitive inhibitors: 
they decreased the affinity of the enzyme for its substrate (Km 
increases), while Vmax was not significantly affected, as shown in 
the examples of Figure 2. The Lineweaver-Burk plots in Figure 2A, 
showed the results obtained for the subseries 4m-4o, taken like 
an example, along with isatin, a well-known competitive MAO 
inhibitor.[34] 
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Figure 2. Competitive inhibition of hrMAO-B by 2-phenyloxazole-4-
carboxamides. A) Double reciprocal plots of hrMAO-B activity in the absence 
(●) and presence of 20M isatin (♦), 4m(▼), 4n(◊) and 4o(○). B) Double 
reciprocal plots of hrMAO-B activity in the absence (●) and in the presence of 
different 4a concentrations (1-10 M). The Ki = 0.9±0.2 µM for the competitive 
mode of inhibition of 4a, was calculated by global fit analysis (GraphPad 5.0 
software). Continuous lines are the result of linear regression analysis of plotted 
data (r >0.98). 
The double reciprocal plots (1/v vs 1/S, Lineweaver-Burk plots) of 
the kinetic data of hrMAO-B in the presence of various 
concentrations (1-10 M) of the lead compound 4a (Figure 2B), 
clearly demonstrate the competitive mode of inhibition, being the 
intercept on the y-axis (1/Vmax) about of the same value for all the 
tested concentrations. This behavior represents the classical 
mode of action of a competitive inhibitor, as confirmed by the 
global fit analysis. 
The inhibition constant values (Ki), which represent the 
dissociation constant values between the MAOs and the new 
derivatives, were determined for both enzymes and were reported 
in Table 1 along with that of isatin. 
The results calculated from the kinetic analysis highlight hrMAO-
B as the preferred isoform target of 4a-o derivatives. In fact, the 
selectivity index (KiMAO-A/KiMAO-B) span from about 3 (4f) to 63 (4a) 
(Table 1). 
Inside each subseries of derivatives (4a-c, 4d-f, 4g-i and 4m-o), 
the most potent and selective hrMAO-B inhibitors are the 
compounds 4a, 4d, 4g and 4m (Ki 0.6-4.3 M for hrMAO-B; Ki 
≥28 M for hrMAO-A and selective index S.I.≥12). It is of note that 
the introduction of bulky groups such as diphenylmethane  (4b, 
4e, 4h and 4n), or of an additional carboxamide functionality (4c, 
4f, 4i and 4o) to the 4-carboxamide linker, lead to a significant 
decrease in hrMAO-B inhibitory capacity. In detail, an increase in 
Ki values from about 2 (4d-f) up to more than 20 times (4m-o) is 
observed by considering the subseries. Indeed, derivative 4m, 
characterized by a chlorine in R1 and a hydroxyl substituent in 
both R2 and R3 appears as the most sensitive with respect to any 
structural modification at the level of the 4-carboxamide side chain. 
Table 1. Inhibition constant values (Ki) of 4a-o for hrMAO-A and hrMAO-B. 
Isatin was used as a reference. 
 
 
 
Cmp R1 R2 
 
R3 
Ki (M) S.I.[a] 
hrMAO-A hrMAO-B 
4a H H Ph 57±8 0.9±0.2 63 
4b H H CH(Ph)2 74±10 5.2±0.7 14 
4c H H CH2CONHPh 90±9 10.0±1.0 9 
4d Cl H Ph 50±7 4.3±0.8 12 
4e Cl H CH(Ph)2 67±7 9.4±1.4 7 
4f Cl H CH2CONHPh 38±8 15.0±2.0 3 
4g H OH Ph 28±4 0.6±0.1 47 
4h H OH CH(Ph)2 71±8 5.0±0.8 14 
4i H OH CH2CONHPh 35±7 4.2±0.3 8 
4m Cl OH Ph 33±4 0.6 ±0.1 55 
4n Cl OH CH(Ph)2 64±7 17.1±2.1 4 
4o Cl OH CH2CONHPh 40±5 14.0±2.0 3 
Isatin[b] - - - 16±3 4.0±1.0 4 
[a] S.I. selectivity index= KihrMAO-A/ KihrMAO-B. [b] reference compound 
 
As regards derivatives 4a, 4d, 4g and 4m, the obtained Ki values 
allowed us to draw some interesting structure-activity 
relationships. In particular, the replacement of the hydrogen in 
position R1 (4a) with a chlorine (4d) causes a notable decrease in 
inhibitory activity, as indicated by an increase in Ki value of about 
5 times. This result suggests a detrimental role of the halogen in 
such position. Nevertheless, the addition of a further hydroxyl 
group in R2 (4m) abolishes such unfavorable effect, indicating an 
important role, in the inhibition of the hrMAO-B activity, of the 
substituent in position R2. The relevance of the hydroxyl 
substituents in R2 and R3 appears supported also by the 
noteworthy Ki value obtained for derivative 4g. 
Finally, it is to note that the more potent and selective derivatives 
(4a, 4g and 4m) are characterized by Ki values of the same order 
of magnitude of others reversible hrMAO-B “cavity-filling” 
inhibitors, like safinamide, used against epilepsy[21] and 
pioglitazone, having IC50 values of about 0.5 M.[35] 
 
Inhibitory effect on MAO-A and MAO-B activities in NGF-
differentiated PC12 cells 
 
NGF–differentiated PC12 cells were chosen as a model of 
neuronal cells to evaluate the effectiveness of the new 2-
phenyloxazole-4-carboxamides. At first, the MAO-B activity was 
evaluated by using deprenyl, a well-known MAO-B irreversible 
inhibitor, and pargyline, irreversible dual MAO-A and -B inhibitor, 
as reference compounds. About 26% of monoamine oxidase 
activity in PC12 cell lysates was found to be inhibited by deprenyl, 
indicating the expression of active MAO-B, in addition to the MAO-
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 A isoform, which is the one to be mainly expressed in 
undifferentiated PC12 cells[36] On the basis of these results, the 
effect of 4a-o was preliminarily tested at 20M concentration, 
using kynuramine (kyn) as substrate ([kyn]=10 M, that is [S]<Km) 
and isatin as reference inhibitor. The measured residual MAO 
activity, expressed as percentage with respect to the control, is 
reported in Table 2. The obtained results suggest that most 
derivatives are active as MAO inhibitor also in a complex matrix 
such as that of the NGF–differentiated PC12 cells lysates. In 
particular, for 4a, 4h and 4m a residual MAO activity lower that 
50% with respect to the control was found, allowing us to highlight 
them as the most interesting derivatives. Notably, for 4a and 4m 
a strong agreement between the inhibitory capacity on cell lysate 
and on hrMAO-B was found. 
Table 2. Inhibitory effect of 4a-o on MAO activity in NGF-differentiated PC12 
cell lysate. 
Compound 
Residual MAO 
activity at 20M 
KiMAOs (M) 
- 1  
4a 0.21 4.7±0.5 
4b 0.90 n.d.[a] 
4c 0.91 n.d 
4d 0.84 n.d 
4e 0.76 n.d 
4f 0.78 n.d 
4g 0.71 48.0±5.1 
4h 0.29 10.0±2.1 
4i 0.72 n.d 
4m 0.40 14.5±1.2 
4n 0.70 45.1±5.0 
4o 0.64 37.8±6.4 
isatin[b] 0.51 20.5±1.8 
[a] n.d: not determined [b] reference compound 
 
For the most interesting compounds, i.e. those for which a 
residual MAO activity lower than 0.71 was detected in PC12 cell 
lysates, the Ki values were also calculated (Table 2). In detail, the 
obtained results indicate 4a as the most effective MAO inhibitor in 
this cellular model (Ki=4.7M), followed by 4h and 4m (10.0 and 
14.5 M, respectively). Conversely, 4o, 4n and 4g appear to be 
less effective inhibitors. 
Overall, these data allow us to highlight 4a as a very interesting 
lead compound that presents notable inhibitory activity both in the 
in vitro hr-MAOB and in the cell model. In this regard, the reduced 
potency of 4a as MAO inhibitor in cells with respect to the human 
recombinant enzyme (Ki=0.9 M vs KiMAOs=4.7M) and the 
differences in inhibitor specificity should be due to two factors: i) 
PC12 cells contain mainly the MAO-A isoform of the enzyme on 
which 4a is significantly less effective (see Table 1, S.I.=63); ii) 
PC12 cells were derived from a rat pheochromocytoma and rat 
MAOs can exert different sensitivity with respect to the human 
ones. Actually, important species-dependent differences in MAO-
B inhibitor specificity between human and rat have been already 
evidenced for other classes of compounds.[37] 
 
Cell viability on HeLa and NGF-differentiated PC12 cells 
 
Based on the significant inhibitory effect on hr-MAO-B, the 2-
phenyloxazole-4-carboxamide derivatives 4a, 4d, 4g, 4h, 4i and 
4m were selected to evaluate their potential cytotoxicity, together 
with the less effective 4n. 
In detail, we investigate if cell viability of HeLa (human cervix 
adenocarcinoma) and NGF-differentiated PC12 (rat 
pheochromocytoma) cells is altered by treatment with these 
compounds at 20 M concentration, that is the experimental 
condition employed for the assay of residual MAO activity in cell 
lysate (see Table 2). The obtained data, expressed as fold change 
with respect to the control culture, indicate that some of them (4d, 
4g, 4m and 4n) can affect significantly cell viability, and that this 
decrease is higher in NGF differentiated PC12 cells, which 
express both MAO-A and MAO-B, compared to HeLa cells, which 
express only MAO-A (Table 3).[38] In particular, 4d and 4g 
drastically reduce cell viability, indicating that their action 
compromises cell survival and induces neuronal cell death. 
Interestingly, the other compounds (4a, 4h and 4i) provoke only a 
mild decrease in cell viability, suggesting that their effect as MAO 
inhibitors did not lead to cell death in this condition. Notably, 
derivative 4a, the most selective toward hrMAO-B (Table 1) and 
the most effective as anti-MAOs in cell lysates (Table 2) shows 
negligible effect on cell viability. 
 
Table 3. Effects of 4a-o on cell viability in HeLa and in NGF-differentiated PC12 
cells 
 Cell viability at 20 µM[a] 
HeLa PC12 
DMSO 1.00 ± 0.02 1.00 ± 0.05 
4a 0.99 ± 0.00 0.93 ± 0.11 
4d 0.88 ± 0.01 0.60 ± 0.03 
4g 1.02 ± 0.02 0.47 ± 0.03 
4h 0.98 ± 0.03 0.85 ± 0.09 
4i 0.92 ± 0.02 0.94 ± 0.07 
4m 0.98 ± 0.00 0.77 ± 0.12 
4n 0.91 ± 0.00 0.72 ± 0.06 
[a] Data are expressed as fold change of controls (DMSO). All values are 
expressed as mean ± SEM. 
Molecular docking studies 
 
Docking calculations were carried out on protein conformations 
whose co-crystallized ligands were on average the most similar to 
the compounds under investigation (Table S1). This approach 
has already demonstrated to help improving binding mode 
predictions in other studies.[39,40] To this aim, 3D similarity 
analyses were carried out as described in the experimental 
 section. Each co-crystallized ligand in the bound conformation 
was used as a query to perform the 3D similarity estimations. A 
visual inspection of the resulting alignments allowed evaluating 
the shape and pharmacophoric feature overlaps between the 
query compounds and the co-crystallized MAO ligands. The 
investigated compounds were found to be different from co-
crystallized ligands, the Tanimoto COMBO similarity scores being 
below 1 for almost all compounds (Table S1). However, shape 
similarities (Shape Tanimoto) were significantly higher than 
pharmacophore similarities (Color Tanimoto), demonstrating that 
the compounds are similar in shape with respect to co-crystallized 
ligands but different in chemical structure. Similarity scores and 
visual inspection of the alignments allowed the identification of 
2Z5X (chain A) and 2V60 (chain B) as the most suitable protein 
conformations for docking in MAO-A and MAO-B isoforms, 
respectively. Figure S1 of the Supporting Information shows the 
superimposition of 4a with the HRM (2Z5X) and the C17 (2V60) 
co-crystallized ligands as predicted by ROCS.[41,21] 
Compounds were docked into the selected MAO active sites and 
the predicted binding modes were used to rationalize the 
experimentally observed binding affinity and selectivity. Figure 3 
shows the binding modes of the most active compounds of the 
series (4a, 4d, 4g and 4m) in the MAO-B active site. 
 
Figure 3. Predicted binding modes of the 4a (panel a), 4d (panel b), 4g (panel 
c) and 4m (panel d) compounds in the MAO-B active site. 
All compounds were able to bind MAO-B with the phenol ring 
moiety oriented towards the FAD cofactor. The 2-hydroxyl group 
of the most active compounds formed direct hydrogen bonds with 
the Tyr435 and Cys172 side chains, in line with interactions 
previously observed for other MAO-B inhibitors.[8] Moreover, the 
amide carbonyl established hydrogen bonds with the Tyr326 side 
chain, an interaction that is recognized to play a key role in MAO-
B isoform selectivity.[8,42] Interestingly, the hydroxyl groups 
participated to an extended network of hydrogen bonds involving 
conserved water molecules. In particular, the 2-hydroxyl group is 
engaged in an h-bond network formed by waters W1193 and 
W1358, Cys172 (backbone carbonyl and side chain), Tyr435 
(side chain) and Gly434 (backbone carbonyl) (Figure 3). The 4-
hydroxyl group, when present, participates to this h-bond network 
by forming direct interactions with W1358. The terminal phenyl 
ring binds to a distal hydrophobic pocket lined by Pro104, Leu164, 
Ile199 and Ile316 residues of MAO-B. Remarkably, the binding 
mode of these compounds is consistent with the structural 
alignment obtained with ROCS (Figure S2), providing evidence 
that structure-based and ligand-based methods converged to 
similar results. Moreover, the binding modes of the most active 
compounds significantly overlapped with the crystallographic 
poses of several inhibitors in complex with the MAO-B protein 
(Figure S3).[8,43] 
Compounds with a bulkier diphenylmethane group (4b, 4e, 4h 
and 4n) were, on average, ten times less potent on MAO-B with 
respect to ligands with a terminal phenyl ring. Docking of these 
compounds revealed steric clashes with residues of the distal 
hydrophobic pocket, resulting in a ~2Å shift of the amide group 
with respect to the phenyl substituted compounds, a loss of the 
Tyr326 hydrogen bond and the placement of one of the two 
phenyl rings in a polar cavity lined by Ser200, Thr201 and Glu84 
which is normally occupied by water molecules. (Figure S4, panel 
a). These differences may explain the lower activity of the 
diphenylmethane derivatives. 
Compounds with a longer N-phenylacetamide moiety (4c, 4f, 4i 
and 4o) were, on average, ten times less active compared to the 
phenyl-substituted compounds. The N-phenylacetamide moiety 
could not be accommodated in an extended conformation 
because of steric clashes with the Pro104 and Leu164 residues 
of the distal MAO-B binding pocket. These compounds could dock 
only after a 180° flip of the amide group and a ~60° tilt of the 
methylene linker. However, this binding mode resulted in the loss 
of the Tyr326 hydrogen bond and in a phenyl ring that was ~2Å 
shifted with respect to the phenyl ring of the more active 
compounds (Figure S4, panel b). Moreover, placement of the 
phenyl ring required a 1.5Å displacement of the Leu164 side chain, 
because of steric repulsion. These differences may explain the 
lower activity of the N-phenylacetamide compounds. 
According to the experimentally determined binding affinities (vide 
supra), selectivity indexes ranged from 3 (4f) to 63 (4a) always in 
favor of MAO-B (Table 1). The most active compounds of the 
series (4a, 4g and 4m) were, on average, 50 times more potent 
on MAO-B rather than MAO-A. The MAO-A and MAO-B binding 
sites are known to differ for a few amino acids, shown in Figure 
S5.[8,42] Docking into MAO-A revealed that the compounds could 
not bind with an orientation similar to that of MAO-B, because of 
significant steric clashes with the Phe208 (Ile199 in MAO-B) side 
chain that partially occludes the MAO-A binding site. As a result, 
the 2-hydroxyl group hydrogen bonds with the Asn181 (Cys172 in 
MAO-B) side chain, but the oxazole ring is ~3Å displaced with 
respect to MAO-B, the hydrogen bond with Tyr326 (Ile335 in 
MAO-A) is lost, and the terminal phenyl ring binds in a position 
that is similar to the orientation of the additional phenyl ring of the 
diphenylmethane derivatives in MAO-B, interacting with Ala11, 
Ser209 and Val210 (Figure S6). Moreover, the phenol ring could 
be accommodated only after displacement of W710 (~1.0Å), 
W739 (~0.8Å), Tyr444 (~0.8Å) and Asn181 (~0.6Å), indicating 
further steric constraints. The lack of a hydrogen bond with the 
Tyr326 residue of MAO-B in particular has been recognized to 
play a key role in isoform selectivity for the two enzymes.[8,42] 
Overall, these differences in the predicted docking poses may 
 explain the experimentally observed selectivity of the compounds 
for MAO-B. 
 
Investigation of the chemical novelty of the reported 
inhibitors 
 
To evaluate the novelty of the discovered compounds, maximum 
common substructure searches (MCSS) and 2D similarity 
analyses were carried out on ChEMBL as described in the 
methods section. Interestingly, substructure analyses indicated 
that derivatives of the 2-(2-hydroxyphenyl)-1,3-oxazole-4-
carboxamide scaffold have not been previously exploited for MAO 
inhibition. Moreover, 2D similarity analyses made with two 
different fingerprint types (MACCS and ECFP6)[44-46] were also 
performed to evaluate to what extent the newly identified 
molecules differ from already reported MAO inhibitors. Results 
from these analyses revealed that the discovered compounds 
were on average non-similar to previously reported MAO 
inhibitors (Table S2).[47,48] Indeed, visual inspection of the closest 
ChEMBL compounds identified through 2D similarity and MCSS 
analyses further demonstrated that the chemical structure of the 
discovered inhibitors is substantially different to that of the MAO 
ligands reported in ChEMBL (Table S3). 
Conclusions 
The preparation of a small library of new 2-phenyloxazole-4-
carboxamides differently substituted at the phenyl ring and 
bearing an amide group at position 4 (compounds 4a-o) is 
described. The biological evaluation highlighted for all derivatives 
the ability to inhibit the hr-MAO-B enzyme activity. In particular, 
compounds 4a, 4g and 4m are low molecular weight inhibitors 
with Ki value significantly lower than that of isatin, taken as 
reference. Interestingly, all derivatives were selective toward the 
MAO-B isoform and, in detail, a Selectivity Index (KiMAO-A/KiMAO-B) 
ranging from 3 to 63 was obtained. The kinetic analysis evidenced 
a competitive mode of inhibition and notably, for the most 
interesting 4a, the inhibitory effect was confirmed also in NGF–
differentiated PC12 cell lysates. Indeed, in this cell model, Ki 
values of 4.7 M and 20.5 M for 4a and isatin, respectively, were 
obtained. Furthermore, the lack of any significant cytotoxicity in 
NGF–differentiated PC12 cells renders the MAO inhibitory effect 
of 4a on cells of particular interest. Finally, molecular modelling 
studies provided insights into the structural determinants 
responsible for the anti-MAO-B activity and selectively, and 
allowed us to evaluate the novelty of the newly synthetized 
compounds. Overall, among the reported ligands 4a may open 
new perspectives for the design and the development of novel 
effective and selective MAO-B inhibitors with potential 
pharmacological applications in the treatment of 
neurodegenerative disorders, such as Parkinson’s disease. 
Experimental Section 
Chemistry: All reactions were carried out in oven-dried glassware and dry 
solvents under nitrogen atmosphere. Unless otherwise stated, all solvents 
were purchased from Sigma Aldrich and used without further purification. 
Substrates and reagents were purchased from Sigma Aldrich and used as 
received. Thin layer chromatography (TLC) was performed on Merck 
precoated 60F254 plates. Reactions were monitored by TLC on silica gel, 
with detection by UV light (254 nm) or by a solution of ninhydrin with 
heating. Flash chromatography was performed using silica gel (240-400 
mesh, Merck). All tested compounds possessed a purity of > 98% 
confirmed via elemental analyses (CHN) in a Perkin Elmer 2400 
instrument. 1H-NMR spectra were recorded on a Bruker DRX-400 and on 
a Varian Oxford 300 MHz spectrometer and are reported relative to 
residual CDCl3 and DMSO. 13C-NMR spectra were recorded on the same 
instrument (100 MHz) and are reported relative to residual CDCl3 and 
DMSO. Chemical shifts (δ) for proton and carbon resonances are quoted 
in parts per million (ppm) relative to tetramethylsilane (TMS), which was 
used as an internal standard. MS spectra were recorded using 
electrospray ionization (ESI) technique on a Waters Micromass Q-Tof 
micro mass spectrometer. 
General procedure for the synthesis of esters 2 
Methyl 2-(2-hydroxyphenyl)oxazole-4-carboxylate (2a):[32] Step A: To a 
mixture of L-serine methyl ester hydrochloride (0.32 g, 2.0 mmol) and 
Mg2SO4 (0.24 g, 2.0 mmol) in THF (10 mL), salicylaldehyde (0.25 g, 2.0 
mmol) and triethylamine (0.56 mL, 4.0 mmol) were added and the resulting 
mixture was stirred overnight at room temperature. After the completion of 
the reaction, the mixture was filtered through celite and the filtrate was 
concentrated to dryness and used for the next step without any further 
purification. 
Step B: To a cooled at 0 °C solution of the filtrate from step A in DCM (10 
mL), bromotrichloromethane (0.60 mL, 6.0 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (0.90 mL, 6.0 mmol) were added, and the 
resulting mixture was stirred for 2 hours at 0 °C and then overnight at room 
temperature. After the completion of the reaction, brine was added and the 
organic phase was extracted 3 times with DCM. The combined organic 
extracts were dried with Na2SO4, filtered and evaporated. The residue was 
purified by flash column chromatography (Hex/DCM 1:1) to provide 
compound 2a as a white amorphous solid (15% yield). 
Methyl 2-(5-chloro-2-hydroxyphenyl)oxazole-4-carboxylate (2b): 
According to the general procedure, ester 2b was obtained from aldehyde 
1b after purification by flash column chromatography (Hex/DCM/MeOH 
5:5:0.5) and evaporation of the solvent as a white amorphous solid (27% 
yield). 1H NMR (300 MHz, DMSO): δ = 10.7 (1H, br. s), 9.04 (1H, s), 7.81 
(1H, d, J 2.7 Hz), 7.48 (1H, dd, J 8.8 Hz J 2.7 Hz), 7.11 (1H, d, J 8.8 Hz), 
3.86 (3H, s); 13C NMR (75 MHz, DMSO): δ = 161.6, 160.6, 156.0, 146.3, 
133.4, 133.2, 128.0, 124.0, 119.9, 113.8, 52.92; ESI-MS: 254.71 (M+H+)+. 
Anal. Calcd for C11H8ClNO4: C, 52.07; H, 3.18; N, 5.52. Found: C, 52.27; 
H, 3.30; N, 5.62. 
Methyl 2-(2,4-dihydroxyphenyl)oxazole-4-carboxylate (2c): According 
to the general procedure, ester 2c was obtained from aldehyde 1c after 
purification by flash column chromatography (EtOAc/DCM/MeOH 5:5:0.5) 
and evaporation of the solvent as a white amorphous solid (24% yield). 1H 
NMR (300 MHz, DMSO): δ = 10.6 (1H, br. s), 10.3 (1H, br. s), 8.91 (1H, s), 
7.67 (1H, d, J 8.2 Hz), 6.48 – 6.45 (2H, m), 3.85 (3H, s); 13C NMR (75 
MHz, DMSO): δ = 162.8, 162.5, 161.6, 159.1, 144.8, 132.5, 129.4, 109.3, 
103.7, 103.2, 52.86; ESI-MS: 236.22 (M+H+)+. Anal. Calcd for C11H9NO5: 
C, 56.16, H, 3.86; N, 5.96. Found: C, 56.27; H, 3.79; N, 5.90. 
Methyl 2-(2,4-bis(benzyloxy)-5-chlorophenyl)oxazole-4-carboxylate 
(2e): According to the general procedure, ester 2e was obtained from 
aldehyde 1e after purification by flash column chromatography 
(Hex/DCM/EtOAc 4.5:5:0.5) and evaporation of the solvent as a white 
amorphous solid (32% yield). 1H NMR (400 MHz, CDCl3): δ = 8.30 (1H, s), 
8.14 (1H, s), 7.50 – 7.35 (10H, m), 6.64 (1H, s), 5.14 (4H, s), 3.97 (3H, 
s);13C NMR (100 MHz, CDCl3): δ = 162.6, 161.0, 157.6, 153.3, 144.2, 
136.8, 136.4, 134.6, 132.3, 129.4 (2C), 129.3 (2C), 129.0, 128.7, 127.7 
(2C), 127.6 (2C), 116.3, 110.5, 101.3, 71.93, 71.71, 52.84; ESI-MS: 472.22 
(M+H+)+. Anal. Calcd for C25H20ClNO5: C, 66.73; H, 4.48; N, 3.11. Found: 
C, 66.87; H, 4.39; N, 3.21. 
 General procedure for the synthesis of acids 3 
2-(2-hydroxyphenyl)oxazole-4-carboxylic acid (3a):[32] To a solution of 
ester 2a (0.20 g, 0.93 mmol) in THF/H2O (12/5 mL) lithium hydroxide 
monohydrate (0.14 g, 3.2 mmol) was added and the reaction mixture was 
refluxed for 3 h. Then THF was evaporated, a solution of HCl 1N was 
added and the organic phase was extracted 3 times with EtOAc. The 
combined organic extracts were washed with brine dried with Na2SO4, 
filtered and evaporated to provide compound 3a as a white amorphous 
solid (92% yield). 
2-(5-chloro-2-hydroxyphenyl)oxazole-4-carboxylic acid (3b): 
According to the general procedure, acid 3b was obtained from ester 2b 
after evaporation of the solvent as a white amorphous solid (91% yield). 
1H NMR (300 MHz, DMSO): δ = 13.3 (1H, br. s), 10.8 (1H, br. s), 8.92 (1H, 
s), 7.78 (1H, d, J 2.8 Hz), 7.45 (1H, dd, J 8.9 Hz J 2.8 Hz), 7.09 (1H, d, J 
8.9 Hz); 13C NMR (75 MHz, DMSO): δ = 161.9, 160.0, 155.6, 145.3, 133.9, 
133.0, 127.1, 123.6, 119.5, 113.1; ESI-MS: 262.63 (M+Na)+. Anal. Calcd 
for C10H6ClNO4: C, 50.11; H, 2.53; N, 5.85. Found: C, 50.31; H, 2.44; N, 
5.75. 
2-(2,4-dihydroxyphenyl)oxazole-4-carboxylic acid (3c): According to 
the general procedure, acid 3c was obtained from ester 2c after 
evaporation of the solvent as a brown amorphous solid (92% yield). 1H 
NMR (300 MHz, DMSO): δ = 13.2 (1H, br. s), 10.7 (1H, br. s), 10.2 (1H, br. 
s), 8.81 (1H, s), 7.66 (1H, d, J 8.5 Hz), 6.48 – 6.44 (2H, m); 13C NMR (75 
MHz, DMSO): δ = 162.4, 162.0, 158.7, 144.9, 133.0, 128.6, 115.8, 108.9, 
103.3, 102.9; ESI-MS: 244.18 (M+Na)+. Anal. Calcd for C10H7NO5: C, 
54.29; H, 3.19; N, 6.34. Found: C, 54.19; H, 3.10; N, 6.42. 
2-(2,4-bis(benzyloxy)-5-chlorophenyl)oxazole-4-carboxylic acid (3e): 
According to the general procedure, acid 3e was obtained from ester 2e 
after evaporation of the solvent as a brown amorphous solid (94% yield). 
1H NMR (400 MHz, DMSO): δ = 13.0 (1H, br. s), 8.83 (1H, s), 7.89 (1H, s), 
7.59 – 7.33 (10H, m), 7.22 (1H, s), 5.35 (2H, s), 5.34 (2H, s); 13C NMR 
(100 MHz, DMSO): δ = 162.6, 159.4, 157.0 (2C), 137.0, 136.5, 134.5, 
130.7, 129.1 (4C), 128.9, 128.7, 128.2 (4C), 127.6, 114.1, 109.7, 101.8, 
71.08, 70.93; ESI-MS: 458.53 (M+Na)+. Anal. Calcd for C24H18ClNO5: C, 
66.12; H, 4.16; N, 3.21. Found: C, 66.31; H, 4.20; N, 3.19. 
General procedure for the synthesis of amides 4 
2-(2-hydroxyphenyl)-N-phenyloxazole-4-carboxamide (4a):[32] To a 
solution of acid 3a (0.067 g, 0.33 mmol) in DCM (10 mL), HATU (0.18 g, 
0.46 mmol) and DIPEA (0.093 mL, 0.52 mmol) were added and the 
reaction was stirred for 30 min at r.t. Then, aniline (0.033 mL, 0.36 mmol) 
was added and the new solution was refluxed for 4 h. After the completion 
of the reaction, sat. NH4Cl was added and the organic phase was extracted 
3 times with DCM. The combined organic extracts were washed with H2O 
and Brine, dried with Na2SO4, filtered and evaporated. The residue was 
purified by flash column chromatography (Hex/EtOAc 7:3) to provide 
amide 4a as a white amorphous solid (85% yield). Anal. Calcd for 
C16H12N2O3: C, 68.56; H, 4.32; N, 9.99. Found: C, 68.73; H, 4.39; N, 9.91. 
N-benzhydryl-2-(2-hydroxyphenyl)oxazole-4-carboxamide (4b):[32] 
According to the general procedure, amide 4b was obtained from acid 3a 
and benzhydrylamine after purification by flash column chromatography 
(Hex/EtOAc 7:3) and evaporation of the solvent as a white amorphous 
solid (80% yield). Anal. Calcd for C23H18N2O3: C, 74.58; H, 4.90; N, 7.56. 
Found: C, 74.79; H, 4.98; N, 7.48. 
2-(2-hydroxyphenyl)-N-(2-oxo-2-(phenylamino)ethyl)oxazole-4-
carboxamide (4c):[31] According to the general procedure, amide 4c was 
obtained from acid 3a and 2-Amino-N-phenylacetamide after purification 
by flash column chromatography (Hex/EtOAc 4:6) and evaporation of the 
solvent as a white amorphous solid (75% yield). Anal. Calcd for 
C18H15N3O4: C, 64.09; H, 4.48; N, 12.46. Found: C, 64.34; H, 4.55; N, 
12.31. 
2-(5-chloro-2-hydroxyphenyl)-N-phenyloxazole-4-carboxamide (4d): 
According to the general procedure, amide 4d was obtained from acid 3b 
and aniline after purification by flash column chromatography (Hex/EtOAc 
8:2) and evaporation of the solvent as a white amorphous solid (70% yield). 
1H NMR (300 MHz, DMSO): δ = 10.5 (1H, s), 8.89 (1H, s), 7.82 – 7.77 (3H, 
m), 7.37 (2H, t, J 8.1 Hz), 7.24 (1H, d, J 4.2 Hz), 7.13 (1H, t, J 7.8 Hz), 
7.00 (1H, d, J 8.7 Hz); 13C NMR (75 MHz, DMSO): δ = 159.2, 158.1, 155.8, 
142.5, 139.1, 137.2, 129.5 (2C), 129.0, 127.7, 124.9, 122.8, 121.6 (2C), 
121.5, 113.9; ESI-MS: 337.25 (M+Na)+. Anal. Calcd for C16H11ClN2O3: C, 
61.06; H, 3.52; N, 8.90. Found: C, 61.29; H, 3.57; N, 3.47. 
N-benzhydryl-2-(5-chloro-2-hydroxyphenyl)oxazole-4-carboxamide 
(4e): According to the general procedure, amide 4e was obtained from acid 
3b and benzhydrylamine after purification by flash column 
chromatography (Hex/EtOAc 7:3) and evaporation of the solvent as a 
white amorphous solid (65% yield). 1H NMR (400 MHz, DMSO): δ = 10.5 
(1H, br. s), 9.62 (1H, d, J 8.8 Hz), 8.84 (1H, s), 7.84 (1H, d, J 2.4 Hz), 7.48 
(1H, dd, J 8.8 Hz J 2.4 Hz), 7.40 – 7.28 (10H, m), 7.11 (1H, d, J 8.8 Hz), 
6.45 (1H, d, J 8.8 Hz); 13C NMR (100 MHz, DMSO): δ = 160.0, 159.8, 156.0, 
143.5, 143.2 (2C), 137.1, 133.7, 129.5 (4C), 128.9 (4C), 128.3 (2C), 127.3, 
124.4, 120.6, 113.4, 56.56; ESI-MS: 427.00 (M+Na)+. Anal. Calcd for 
C23H17ClN2O3: C, 68.24; H, 4.23; N, 6.92. Found: C, 68.40; H, 4.31; N, 
6.81. 
2-(5-chloro-2-hydroxyphenyl)-N-(2-oxo-2-
(phenylamino)ethyl)oxazole-4-carboxamide (4f): According to the 
general procedure, amide 4f was obtained from acid 3b and 2-Amino-N-
phenylacetamide after purification by flash column chromatography 
(DCM/MeOH 95:5) and evaporation of the solvent as a white amorphous 
solid (60% yield). 1H NMR (400 MHz, DMSO): δ = 10.5 (1H, s), 10.1 (1H, 
s), 9.12 (1H, t, J 6.0 Hz), 8.82 (1H, s), 7.86 (1H, d, J 2.8 Hz), 7.61 (2H, d, 
J 7.6 Hz), 7.50 (1H, dd, J 9.2 Hz J 2.8 Hz), 7.32 (2H, t, J 7.6 Hz), 7.14 (1H, 
d, J 9.2 Hz), 7.04 (1H, t, J 7.6 Hz), 4.09 (2H, d, J 6.0 Hz); 13C NMR 
(100MHz, DMSO): δ = 167.9, 160.4, 159.5, 157.6 (from HMBC), 151.5 
(from HMBC), 142.3 (from HSQC), 139.4, 136.5, 132.9, 129.2 (3C), 127.0, 
123.7, 119.6 (2C), 113.0, 42.95; ESI-MS: 394.06 (M+Na)+. Anal. Calcd for 
C18H14ClN3O4: C, 58.15; H, 3.80; N, 11.30. Found: C, 58.31; H, 3.89; N, 
11.20. 
2-(2,4-dihydroxyphenyl)-N-phenyloxazole-4-carboxamide (4g): 
According to the general procedure, amide 4g was obtained from acid 3c 
and aniline after purification by flash column chromatography (DCM/MeOH 
98:2) and evaporation of the solvent as a white amorphous solid (60% 
yield). 1H NMR (300 MHz, DMSO): δ = 10.35 (1H, br. s), 10.32 (1H, br. s), 
10.2 (1H, br. s), 8.77 (1H, s), 7.76 (2H, d, J 7.5 Hz), 7.67 (1H, d, J 8.7 Hz), 
7.36 (2H, t, J 7.5 Hz), 7.12 (1H, t, J 7.5 Hz), 6.46 (1H, dd, J 8.7 Hz J 2.4 
Hz), 6.42 (1H, d, J 2.4 Hz); 13C NMR (75 MHz, DMSO): δ = 162.4, 161.0, 
158.6, 158.5, 141.8, 138.6, 136.2, 129.0 (2C), 128.6, 124.6, 121.4 (2C), 
108.9, 103.5, 102.9; ESI-MS: 318.95 (M+Na)+. Anal. Calcd for C16H12N2O4: 
C, 64.86; H, 4.08; N, 9.46. Found: C, 65.04; H, 4.12; N, 9.39. 
N-benzhydryl-2-(2,4-dihydroxyphenyl)oxazole-4-carboxamide (4h): 
According to the general procedure, amide 4h was obtained from acid 3c 
and benzhydrylamine after purification by flash column chromatography 
(DCM/MeOH 98:2) and evaporation of the solvent as a white amorphous 
solid (60% yield). 1H NMR (300 MHz, DMSO): δ = 10.4 (1H, br. s), 10.2 
(1H, br. s), 9.54 (1H, d, J 9.0 Hz), 8.67 (1H, s), 7.66 (1H, d, J 8.6 Hz), 7.37 
– 7.27 (10H, m), 6.48 – 6.41 (3H, m); 13C NMR (75 MHz, DMSO): δ = 162.7, 
161.3, 159.9, 158.8, 142.6 (2C), 141.6, 136.3, 129.7, 129.2 (4C), 128.6 
(4C), 128.1, 128.0, 109.3, 103.9, 103.3, 56.24; ESI-MS: 409.17 (M+Na)+. 
Anal. Calcd for C23H18N2O4: C, 71.49; H, 4.70; N, 7.25. Found: C, 71.73; 
H, 4.79; N, 7.17. 
2-(2,4-dihydroxyphenyl)-N-(2-oxo-2-(phenylamino)ethyl)oxazole-4-
carboxamide (4i): According to the general procedure, amide 4i was 
obtained from acid 3c and 2-Amino-N-phenylacetamide after purification 
by flash column chromatography DCM/MeOH 9:1) and evaporation of the 
solvent as a white amorphous solid (50% yield). 1H NMR (400 MHz, 
DMSO): δ = 10.8 (1H, br. s), 10.1 (1H, br. s), 9.20 (1H, t, J 6.0 Hz), 8.84 
 (1H, s), 8.01 (1H, d, J 8.8 Hz), 7.61 (2H, d, J 8.0 Hz), 7.32 (2H, t, J 8.0 Hz), 
7.12 (1H, d, J 2.4 Hz), 7.06 (1H, t, J 7.6 Hz), 6.98 (1H, dd, J 8.8 Hz J 2.4 
Hz), 4.10 (2H, d, J 6.0 Hz);13C NMR (100 MHz, DMSO): δ = 168.5, 160.8, 
160.1, 159.2, 156.5, 142.1 (from HSQC), 140.0, 136.9, 130.4, 129.9 (2C), 
124.4, 120.2 (2C), 110.4, 110.0, 107.5, 43.54; ESI-MS: 376.35 (M+Na)+. 
Anal. Calcd for C18H15N3O5: C, 61.19; H, 4.28; N, 11.89. Found: C, 61.33; 
H, 4.34; N, 11.80. 
2-(2,4-bis(benzyloxy)-5-chlorophenyl)-N-phenyloxazole-4-
carboxamide (4j): According to the general procedure, amide 4j was 
obtained from acid 3e and aniline after purification by flash column 
chromatography (Hex/EtOAc 8:2) and evaporation of the solvent as a 
white amorphous solid (70% yield). 1H NMR (300 MHz, DMSO): δ =9.99 
(1H, br. s), 8.08 (1H, s), 8.01 (1H, s), 7.78 (2H, d, J 7.5 Hz), 7.54 – 7.31 
(12H, m), 7.12 (1H, t, J 7.5 Hz), 6.59 (1H, s), 5.37 (2H, s), 5.34 (2H, s); 13C 
NMR (75 MHz, DMSO): δ = 162.1, 160.3, 157.9, 157.4, 143.5, 137.3, 137.1, 
136.8, 136.6, 130.1, 129.5 (4C), 129.0 (2C), 128.6 (2C), 128.5 (4C), 128.0, 
121.6 (2C), 115.4, 110.0, 101.7, 71.55, 71.43; ESI-MS: 533.71 (M+Na)+. 
Anal. Calcd for C30H23ClN2O4: C, 70.52; H, 4.54; N, 5.48. Found: C, 70.77; 
H, 4.60; N, 5.46. 
N-benzhydryl-2-(2,4-bis(benzyloxy)-5-chlorophenyl)oxazole-4-
carboxamide (4k): According to the general procedure, amide 4k was 
obtained from acid 3e and benzhydrylamine after purification by flash 
column chromatography (Hex/EtOAc 8:2) and evaporation of the solvent 
as a white amorphous solid (70% yield). 1H NMR (400 MHz, CDCl3): δ = 
8.27 (1H, s), 8.02 (1H, s), 7.62 (1H, d, J 8.8 Hz), 7.46 – 7.26 (20H, m), 
6.68 (1H, s), 6.48 (1H, d, J 8.8 Hz), 5.20 (2H, s), 5.12 (2H, s); 13C NMR 
(100 MHz, CDCl3): δ = 160.6, 159.8, 157.5, 157.2, 141.9 (2C), 141.6, 137.4, 
136.6, 136.3, 132.0, 129.4 (8C), 129.3 (2C), 129.0, 128.8, 128.3 (4C), 
128.2 (2C), 127.7, 127.6, 116.2, 110.7, 101.5, 72.04, 71.75, 57.04; ESI-
MS: 624.38 (M+Na)+. Anal. Calcd for C37H29ClN2O4: C, 73.93; H, 4.86; N, 
4.66. Found: C, 74.22; H, 4.94; N, 4.60. 
2-(2,4-bis(benzyloxy)-5-chlorophenyl)-N-(2-oxo-2-
(phenylamino)ethyl)oxazole-4-carboxamide (4l): According to the 
general procedure, amide 4l was obtained from acid 3e and 2-Amino-N-
phenylacetamide after purification by flash column chromatography 
(Hex/EtOAc 4:6) and evaporation of the solvent as a white amorphous 
solid (50% yield). 1H NMR (400 MHz, CDCl3): δ =8.54 (1H, br. s), 8.27 (1H, 
s), 8.04 (1H, s), 7.69 (1H, t, J 6.0 Hz), 7.56 (2H, d, J 8.0 Hz), 7.49 – 7.31 
(12H, m), 7.12 (1H, t, J 7.6 Hz), 6.67 (1H, s), 5.18 (2H, s), 5.16 (2H, s), 
4.26 (2H, d, J 6.0 Hz); 13C NMR (100 MHz, CDCl3): δ = 166.9, 162.0, 159.2, 
157.0, 156.7, 140.7 (HSQC), 137.6, 136.1, 136.0, 135.6, 131.1, 129.0 (2C), 
128.8 (2C), 128.7 (2C), 128.4, 128.3, 127.1 (4C), 124.4, 120.2 (2C), 115.8, 
109.8, 100.9, 71.51, 71.08, 44.57; MS: 591.05 (M+Na)+. Anal. Calcd for 
C32H26ClN3O5: C, 67.66; H, 4.61; N, 7.40. Found: C, 67.88; H, 4.68; N, 
7.34. 
General procedure for the deprotection of amides 4j-l 
2-(5-chloro-2,4-dihydroxyphenyl)-N-phenyloxazole-4-carboxamide 
(4m): To a cold at -78 °C solution of amide 4j (0.060 g, 0.12 mmol) in DCM 
(8.3 mL), BBr3 1.0 M in DCM (0.26 mL, 0.26 mmol, 1.1 equiv per bond) 
was added dropwise and the reaction was kept for another 1 h at the same 
temperature and then overnight at r.t. Then, the solution was cooled at 
0 °C, neutralized with MeOH and HCl 1 N was added. The organic phase 
was extracted twice with DCM. The combined organic extracts were 
washed with water and brine, dried with Na2SO4, filtered and evaporated. 
The residue was purified by flash column chromatography (Hex/EtOAc 
7:3) to provide analogue 4m as a white amorphous solid (85% yield). 1H 
NMR (400 MHz, DMSO): δ = 11.0 (1H, br. s), 10.4 (1H, br. s), 10.3 (1H, br. 
s), 8.81 (1H, s), 7.79 (1H, s), 7.78 (2H, d, J 8.8 Hz), 7.38 (2H, t, J 7.6 Hz), 
7.14 (1H, t, J 7.6 Hz), 6.67 (1H, s); 13C NMR (100 MHz, DMSO): δ = 160.5, 
159.3, 158.1, 157.5, 143.0, 139.2, 137.1, 129.8 (2C), 128.9, 125.3, 122.0 
(2C), 112.9, 105.5, 104.7; ESI-MS: 353.75 (M+Na)+. Anal. Calcd for 
C16H11ClN2O4: C, 58.11; H, 3.35; N, 8.47. Found: C, 58.36; H, 3.40; N, 
8.41. 
N-benzhydryl-2-(5-chloro-2,4-dihydroxyphenyl)oxazole-4-
carboxamide (4n): According to the general procedure, amide 4n was 
obtained from amide 4k after purification by flash column chromatography 
(Hex/EtOAc 6:4) and evaporation of the solvent as a white amorphous 
solid (85% yield). 1H NMR (400 MHz, DMSO): δ = 11.0 (1H, br. s), 10.4 
(1H, br. s), 9.55 (1H, d, J 8.8 Hz), 8.72 (1H, s), 7.75 (1H, s), 7.40 – 7.28 
(10H, m), 6.63 (1H, s), 6.45 (1H, d, J 8.8 Hz); 13C NMR (100 MHz, DMSO): 
δ = 160.4, 160.1, 158.0, 157.4, 142.9 (3C), 136.8, 129.5 (4C), 128.9 (4C), 
128.6, 128.3 (2C), 112.8, 105.5, 104.8, 56.52; ESI-MS: 443.87 (M+Na)+. 
Anal. Calcd for C23H17ClN2O4: C, 65.64; H, 4.07; N, 6.66. Found: C, 65.89; 
H, 4.14; N, 6.59. 
2-(5-chloro-2,4-dihydroxyphenyl)-N-(2-oxo-2-
(phenylamino)ethyl)oxazole-4-carboxamide (4o): According to the 
general procedure, amide 4o was obtained from amide 4l after purification 
by flash column chromatography (Hex/EtOAc 4:6) and evaporation of the 
solvent as a white amorphous solid (80% yield). 1H NMR (400 MHz, 
DMSO): δ = 11.0 (1H, br. s), 10.4 (1H, br. s), 10.1 (1H, br. s), 9.07 (1H, t, 
J 6.0 Hz), 8.70 (1H, s), 7.77 (1H, s), 7.60 (2H, d, J 8.0 Hz), 7.32 (2H, t, J 
8.0 Hz), 7.06 (1H, t, J 7.2 Hz), 6.66 (1H, s), 4.07 (2H, d, J 6.0 Hz); 13C 
NMR (100 MHz, DMSO): δ = 168.7, 161.0, 160.1, 158.0, 157.5, 141.6 
(HSQC), 140.0, 136.8, 129.9 (2C), 128.7, 124.4, 120.2 (2C), 112.8, 105.4, 
104.8, 30.11; ESI-MS: 410.80 (M+Na)+. Anal. Calcd for C18H14ClN3O5: C, 
55.75; H, 3.64; N, 10.84. Found: C, 55.97; H, 3.70; N, 10.77. 
Biological evaluation 
Monoamine oxidase activity assays: Human recombinant MAO A and 
MAO B (hrMAO-A and hrMAO-B, respectively) expressed in baculovirus 
infected BT1 cells (5 mg/mL) and horseradish peroxidase were purchased 
from Fluka-Sigma-Aldrich s.r.l. (Italy). Monoamine oxidase activity was 
determined by two different methods: i) by detecting the H2O2 generation 
rate by the peroxidase-coupled continuous assay that uses the Amplex 
Red reagent, as fluorigenic substrate for the peroxidase,[49] ii) by using kyn 
as substrate and measuring the formation of 4-hydroxyquinoline as 
reaction product of MAO activity.[50] The kyn assay was used both to verify 
with a different method the inhibition by the various compounds with 
human MAOs and for the assays of monoamine oxidase activity in PC12 
cells lysates. 
All MAOs activity assays were carried out in Hepes 50 mM, KCl 50 mM, 
NaCl 120 mM, pH 7.4 and at 37°C, as previously reported.[20] 
The assays monitoring the H2O2 production rate were carried out in a final 
volume of 800 l, in the presence of Amplex Red (100 M) and horseradish 
peroxidase type II (5 UmL-1), and using p-tyramine (p-Tyr) (0.1-1.4 mM) 
and benzylamine (BZA) (0.1-15 mM) as MAO-A and MAO-B substrate, 
respectively. Initial velocities were determined by measuring the increase 
in fluorescence intensity (exc= 563nm and em= 586 nm); H2O2 generation 
rate was calculated from the change in fluorescence intensity, by means 
of calibration curves obtained by serial dilution of stock solution of H2O2, in 
the presence of the various substrate concentration and of compounds 4 
in absence of MAO enzyme. 
MAO activity assay with the kyn method was carried out as previously 
described, with minor modifications.[50] Briefly: enzyme stock solutions 
were diluted with assay buffer to get a final concentration 0.006 mg/mL for 
hrMAO-A, 0.04 mg/mL for hrMAO-B, or 0.4 mg/mL for PC12 lysates (in 
200 L), in the presence or absence of the various inhibitors. After 5 min 
of pre-incubation with the compounds, the substrate (kyn) was added at a 
final concentration of 10 M (first-order conditions, [kyn]<Kmkyn, being 
Kmkyn=139±39 and 112±25 M for hrMAO-A and hrMAO-B, respectively 
and Kmkyn=40±10 for MAOs in PC12 lysates). After 45 min incubation at 
37°C, the reaction was stopped by addition of 2M NaOH (80 L) and 480 
L of distilled water. Kyn deaminated by MAOs spontaneously cyclises to 
give 4-hydroxyquinoline, the amount of which was determined by the 
fluorescence intensity of the peak of its emission spectra (exc= 330 nm 
and em330-530 nm), using a specific calibration curve built with the 
standard 4-hydroxyquinoline. 
 The relative amounts of MAO-B activity expressed in lysates from PC12 
cells was evaluated by measuring amine oxidase activity, after 15 minutes 
of pre-incubation with deprenyl (2 M), irreversible and selective MAO-B 
inhibitors, before adding the substrate (kyn=300M, saturating substrate 
concentration). A control sample, pre-incubated in the absence of inhibitor, 
was taken as reference control and a sample pre-incubated with pargyline 
(125M) irreversible MAO inhibitor was taken as reference sample of fully 
inhibited MAO activity. A sample without enzyme was always run and 
taken as “blank sample”. A relative amount of about 26% of MAO-B activity 
was found in PC12 cell lysates (74% of residual MAO activity after 
deprenyl pre-incubation). 
The following stock solutions were used: compounds 4 and isatin 
(reference competitive MAO inhibitor) (20mM) in DMSO; the standard 
irreversible MAOs inhibitors deprenyl and pargyline (10 mM) in water. 
The protein content of samples was measured by the Bradford method, 
with bovine serum albumin as standard.[51] 
A Cary-Eclipse fluorimeter (Varian Inc., Palo Alto, CA, USA) and a Cary 
50 Scan UV-visible were used for fluorimetric and spectrophotometric 
measurements, respectively. 
 
MAO inhibition kinetic parameters: Steady-state kinetic parameters 
(Vmax and Km) were calculated by fitting the Michaelis-Menten equation to 
the experimental data (initial rate of reactions (V0) vs substrate 
concentrations) by non-linear regression analysis, with Sigma Plot 
software, version 9.0 (Jandel Scientific, San Rafael, CA, USA) and the 
value of the kinetic parameter obtained from the best fit and its S.E.M. are 
reported. 
The apparent Vmax and Km values of hrMAO-A and hrMAO-B were 
determined in the presence of the different concentrations of the various 
compounds. The mode of inhibition was determined by global fit analysis 
(GraphPad 5.0 software) of the initial rate of reaction (V0) vs substrate 
concentration plots, in the presence and absence of inhibitor, to fit 
equations for competitive, mixed, non-competitive and uncompetitive 
inhibition models; the fit giving the highest r2 value was selected for the 
calculation of inhibition constants (Ki). The results are presented as double 
reciprocal Lineweaver-Burk plots (1/v vs 1/S) to show the competitive 
mode of inhibition of the tested compounds. 
Inhibitory activity of compounds on MAO in PC12 cell lysates was 
evaluated by using a fixed concentration (20 M) of each compound; 
results are presented as residual MAO activity with respect to control 
sample. Ki values for MAOs in PC12 lysates were determined for some of 
the more effective compounds. 
Unless stated otherwise, the correlation coefficient for linear regression 
was 0.98 or greater. 
All experiments were performed at least in triplicate, and the experimental 
data were expressed as the mean ± standard deviation (SD). 
Cell cultures, extraction and treatments: HeLa (human cervix 
adenocarcinoma) cells were grown in DMEM (ECM0101L, Euroclone) 
supplemented with 10% Fetal Bovine Serum (ECS0180LI, Euroclone), 2 
mM L-Glutamine (ECB3000D, Euroclone), 200 μg/mL 
Penicillin/Streptomycin (ECB3001D, Euroclone). PC12 (rat 
pheochromocytoma) cells were routinely maintained in RPMI 1640 
medium (ECB9006L, Euroclone) supplemented with 10% Horse Serum 
(ECS0090D, Euroclone), 5% Fetal Clone Serum (HyClone, SH30066.02, 
ThermoFisher), 2 mM L-Glutamine, 200 μg/mL Penicillin/Streptomycin. To 
induce neuronal differentiation in PC12 cells, 50 ng/mL of human β-Nerve 
Growth Factor (NGF, 450-01, PeproTech Inc.) were added to the low-
serum differentiation medium (RPMI 1640 supplemented with 1% Horse 
serum, 200 g/mL Penicillin/Streptomycin, 2 mM L-glutammine). PC12 
cells were plated at a density of 120.000 cells/well in a 12 multiwell plate 
previously coated with poli-L-Lysine (P4707, SIGMA-Aldrich). 
Differentiation medium has been replaced every two days. Cells were 
incubated at 37°C, in a humidified atmosphere, 5% CO2. 
To obtain cellular extracts of PC12 cells for the monoamine oxidase activity 
assay, after eight days in differentiation medium, NGF-differentiated cells 
were gently washed twice with PBS and lysed with 20 mM Hepes, pH 7.4, 
in presence of Protease Inhibitors (M250, AMRESCO). Cellular extracts 
were immediately frozen in liquid nitrogen and stored at -80°C. 
To evaluate compound effects on living cells, HeLa and NGF-differentiated 
PC12 cells were plated into 12-well cell culture plates at a density of 
210,000 cells/well and 120,000 cells/well respectively. Compounds were 
tested on HeLa cells the day after seeding or in NGF-differentiated PC12 
cells at 8DIV. Before treatments, both HeLa and PC12 culture media were 
replaced with fresh media and compounds were added to obtain a final 
concentration of 20 µM. Stock solutions of compounds were made in 
dimethylsulfoxide (DMSO), used as control. Treated cells were incubated 
for additional 48 hours at 37°C, and then MTT (3-(4,5-dimethylthiazol)-2,5-
diphenyltetrazolium bromide, M2128, SIGMA-Aldrich) assay was 
performed to test cell viability. The intensity of the solution is measures at 
a wavelength of 570 nm using a plate reader spectrophotometer (Infinite 
200Pro, Tecan). 
Molecular Modeling 
Proteins and co-crystallized ligands preparation: Crystal structures of 
human Monoamine Oxidase A (MAO-A) and Monoamine Oxidase B 
(MAO-B) proteins were first downloaded from the Protein Data Bank 
(accessed on January 24th, 2018), resulting in 4 and 40 crystal structures 
for MAO-A and MAO-B, respectively. Structures were subsequently split 
into their chains, leading to two datasets of 6 (MAO-A) and 88 (MAO-B) 
distinct structures (Table S4).[52] Afterwards, the structures were aligned 
and prepared for the subsequent calculations by using the Protein 
Structure Alignment and Protein Preparation Wizard utilities available 
within Maestro 10.3 of the Schrödinger suite (release 2014-3), 
respectively.[53-58] Missing amino acid side chains and hydrogen atoms 
were first added and mismatches in the atom types and bond connectivity 
were fixed. Then, ligand-protein geometries were optimized through a 
restrained minimization, employing a 0.3 Å root mean square threshold. 
Finally, co-crystallized ions and organic solvent molecules were removed 
from the prepared complexes. Flavin-adenine dinucleotide (FAD) cofactor 
and congeners were considered as part of the MAO structures during the 
docking calculations.[59] 
Ligand similarity and protein conformation selection: Docking 
calculations were performed on representative crystal structures whose 
ligands were on average the most similar to the newly identified inhibitors. 
The 3D similarity estimations were performed as follows. Co-crystallized 
ligands were first extracted from the prepared crystal structures in their 
bound conformation, leading to two datasets of 6 and 79 ligands of MAO-
A and MAO-B, respectively. Then, the extracted ligands were used as 
reference queries for the 3D similarity estimations. The MAO inhibitors 
identified in this work were first prepared by using the LigPrep (version 3.5) 
utility available within the Schrödinger suite (release 2014-3).[53,59] 
Ionization states and tautomers potentially present at physiological pH 
were assigned and ligand structures were minimized. Afterwards, a 
conformational sampling was performed for each ligand with the OMEGA2 
software (version 2.5.1.4).[60,61] Up to 400 conformers per compound were 
generated for the ligands, using defaults parameters. 
Ligand similarity was performed by using the ROCS software (version 
3.2.1.4).[62,63] Twenty random starting positions were set for the initial 
ligand alignment to better assess the ligand similarity. The Tanimoto 
COMBO score, which takes into account shape (ShapeTanimoto) and 
chemical pattern (ColorTanimoto) similarities, was used to quantify 3D 
ligand similarity (Table S1). A final step of visual inspection of the ligand 
 alignments led to the selection of two active site conformations to be used 
for docking, i.e. 2Z5X chain A for MAO-A, and 2V60 chain B for MAO-
B.[41,21] 
Docking calculations: Docking calculations were performed on the active 
site of the prepared protein structures by using the Glide (version 6.8) 
docking program.[64,65] All water molecules were removed from the 
selected active sites, except for W1193, W1249 and W1358 in MAO-B and 
W710, W725 and W739 in MAO-A crystal structures (residue numbering 
refers to 2V60 for MAO-B and 2Z5X for MAO-A). These water molecules 
are highly conserved across mono-amino oxidase crystal structure 
complexes. Active sites grids (outer box of 10 Å × 10 Å × 10 Å) were 
centered on the centroids of the bound ligands and generated using 
defaults settings. The docking protocol was first validated by redocking the 
HRM and C17 ligands co-crystallized in the 2Z5X and 2V60 crystal 
structures, respectively.[41,21] Then, docking calculations were performed 
and the resulting docking poses were visually inspected. 
Control calculations: To evaluate the novelty of the discovered MAO 
inhibitors with respect to previously reported ligands, 2D similarity 
analyses between the reported compounds and ligands taken from the 
ChEMBL database (release 23, accessed on April 3th, 2018) were 
performed.[66,67] Only annotations with a ChEMBL assay confidence score 
equal or greater than 8 were considered. MACCS and ECFP6 fingerprints 
available within the OpenEye OEGraphSim Python Toolkits were used for 
the similarity calculations.[68,69,47,48] The chemical structures of the newly 
identified MAO inhibitors were used as reference queries for the similarity 
evaluations. A total of 2 (2D fingerprint types MACCS and ECFP6) x 12 
(compounds) = 24 ranks were obtained. Ligand similarity was evaluated in 
terms of the Tanimoto similarity score. Table S2 reports the averaged 
similarities of the newly identified compounds with respect to the already 
known MAO-A and MAO-B inhibitors extracted from the ChEMBL 
database. 
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